Publication:
Distribution of RET mutations and evaluation of treatment approaches in hereditary medullary thyroid carcinoma in Turkey

dc.contributor.authorAydoğan, Berna İmge
dc.contributor.authorYüksel, Bağdagül
dc.contributor.authorTuna, Mazhar Müslüm
dc.contributor.authorBaşaran, Mehtap Navdar
dc.contributor.authorErtörer, Melek Eda
dc.contributor.authorAydın, Kadriye
dc.contributor.authorGuldiken, Sibel
dc.contributor.authorŞimşek, Yasin
dc.contributor.authorKaraca, Züleyha Cihan
dc.contributor.authorYılmaz, Merve
dc.contributor.authorAktürk, Mujde
dc.contributor.authorAnaforoğlu, İnan
dc.contributor.authorKebapcı, Nur
dc.contributor.authorDuran, Cevdet
dc.contributor.authorTaşlıpınar, Abdullah
dc.contributor.authorKulaksızoğlu, Mustafa
dc.contributor.authorGursoy, Alptekin
dc.contributor.authorDağdelen, Selçuk
dc.contributor.authorErdoğan, Murat Faik
dc.contributor.buuauthorKocaeli, Ayşen Akkurt
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentEndokrinoloji ve Metabolizma Ana Bilim Dalı
dc.contributor.scopusid57142602300
dc.date.accessioned2022-12-19T07:12:14Z
dc.date.available2022-12-19T07:12:14Z
dc.date.issued2015-09-30
dc.description.abstractObjective: This retrospective multicenter study, centrally conducted and supported by the Society of Endocrinology and Metabolism of Turkey, aimed to evaluate the impact of free RET proto-oncogene testing in medullary thyroid carcinoma (MTC) patients. Surgical timing, adequacy of the treatment, and frequency of prophylactic thyroidectomy (PTx) in mutation carriers were also assessed. Methods: Genetic testing for MTC and pheochromocytoma was conducted between July 2008 and January 2012 in 512 patients. Application forms and RET mutation analyses of these patients whose blood samples were sent from various centers around Turkey were assessed retrospectively. An evaluation form was sent to the physicians of the eligible 319 patients who had confirmed sporadic MTC, familial MTC (FMTC), multiple endocrine neoplasia type 2 (MEN2), or who were mutation carriers. Physicians were asked to give information about the surgical history, latest calcitonin levels, morbidity, mortality, genetic screening, and PTx among family members. Twenty-five centers responded by filling in the forms of 192 patients. Results: Among the 319 patients, RET mutation was detected in 71 (22.3%). Cys634Arg mutation was the most prevalent mutation (43.7%), followed by Val804Met in 18 patients (25.4%), and Cys634Tyr in 6 patients (8.5%). Among 192 MTC patients, the diagnosis was sporadic MTC in 146 (76.4%), FMTC in 14 (7.3%), MEN2A in 15 patients (7.9%), and MEN2B in one patient. The number of mutation carriers among 154 apparently sporadic MTC patients was 8 (5.2%). Ten patients were submitted to PTx out of twenty-four mutation carriers at a mean age of 35 +/- 19 years. Conclusion: Turkish people have a similar RET proto-oncogene mutation distribution when compared to other Mediterranean countries. Despite free RET gene testing, the number of the PTx in Turkey is limited and relatively late in the life span of the carriers. This is mainly due to patient and family incompliance and incomplete family counselling.
dc.description.sponsorshipSEMT
dc.identifier.citationAydoğan, B. İ. vd. (2016). "Distribution of RET mutations and evaluation of treatment approaches in hereditary medullary thyroid carcinoma in Turkey". Journal of Clinical Research in Pediatric Endocrinology, 8(1), Special Issue,13-20.
dc.identifier.endpage20
dc.identifier.issn1308-5727
dc.identifier.issn1308-5735
dc.identifier.issue1, Special Issue
dc.identifier.pubmed26758973
dc.identifier.scopus2-s2.0-84959185956
dc.identifier.startpage13
dc.identifier.urihttps://doi.org/10.4274/jcrpe.2219
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805043/
dc.identifier.urihttp://hdl.handle.net/11452/29946
dc.identifier.volume8
dc.identifier.wos000378168600002
dc.indexed.scopusScopus
dc.indexed.trdizinTrDizin
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherGalenos Yayıncılık
dc.relation.collaborationYurt içi
dc.relation.collaborationSanayi
dc.relation.journalJournal of Clinical Research in Pediatric Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEndocrinology & metabolism
dc.subjectPediatrics
dc.subjectSporadic medullary thyroid carcinoma
dc.subjectHereditary medullary thyroid carcinoma
dc.subjectMultiple endocrine neoplasia
dc.subjectRET mutation
dc.subjectEndocrine neoplasia type-2
dc.subjectProtooncogene mutations
dc.subjectMen 2a
dc.subjectPrevalence
dc.subjectFamilies
dc.subjectCancer
dc.subjectGuidelines
dc.subjectManagement
dc.subjectExperience
dc.subjectPhenotype
dc.subject.emtreeCalcitonin
dc.subject.emtreeBiological marker
dc.subject.emtreeProtein ret
dc.subject.emtreeRET protein, human
dc.subject.emtreeSorafenib
dc.subject.emtreeAdolescent
dc.subject.emtreeAdult
dc.subject.emtreeAgar gel electrophoresis
dc.subject.emtreeArticle
dc.subject.emtreeChild
dc.subject.emtreeFemale
dc.subject.emtreeGene mutation
dc.subject.emtreeGenetic screening
dc.subject.emtreeHuman
dc.subject.emtreeLymph node dissection
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMetastasis
dc.subject.emtreeMiddle aged
dc.subject.emtreeMorbidity
dc.subject.emtreeMortality
dc.subject.emtreeMultiple endocrine neoplasia type 2
dc.subject.emtreeOncogene ret
dc.subject.emtreeOperation duration
dc.subject.emtreePheochromocytoma
dc.subject.emtreePolymerase chain reaction
dc.subject.emtreeProto oncogene
dc.subject.emtreeRetrospective study
dc.subject.emtreeThyroid medullary carcinoma
dc.subject.emtreeThyroidectomy
dc.subject.emtreeTurkey (republic)
dc.subject.emtreeYoung adult
dc.subject.emtreeCarcinoma, medullary
dc.subject.emtreeClinical trial
dc.subject.emtreeDna mutational analysis
dc.subject.emtreeFollow up
dc.subject.emtreeGenetic predisposition
dc.subject.emtreeGenetics
dc.subject.emtreeHeterozygote
dc.subject.emtreeMulticenter study
dc.subject.emtreeMultiple endocrine neoplasia type 2a
dc.subject.emtreeMutation
dc.subject.emtreePathology
dc.subject.emtreePrognosis
dc.subject.emtreeThyroid neoplasms
dc.subject.emtreeTurkey
dc.subject.meshAdult
dc.subject.meshBiomarkers
dc.subject.meshCarcinoma, medullary
dc.subject.meshDNA mutational analysis
dc.subject.meshFemale
dc.subject.meshFollow-up studies
dc.subject.meshGenetic predisposition to disease
dc.subject.meshHeterozygote
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMultiple endocrine neoplasia type 2a
dc.subject.meshMutation
dc.subject.meshPrognosis
dc.subject.meshProto-oncogene proteins c-ret
dc.subject.meshRetrospective studies
dc.subject.meshThyroid neoplasms
dc.subject.meshThyroidectomy
dc.subject.meshTurkey
dc.subject.scopusThyroid Medullary Carcinoma; Thyroid Neoplasms; Calcitonin
dc.subject.wosEndocrinology & metabolism
dc.subject.wosPediatrics
dc.titleDistribution of RET mutations and evaluation of treatment approaches in hereditary medullary thyroid carcinoma in Turkey
dc.typeArticle
dc.wos.quartileQ4 (Endocrinology & metabolism)
dc.wos.quartileQ3 (Pediatrics)
dc.wos.quartileQ4
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Endokrinoloji ve Metabolizma Ana Bilim Dalı
local.indexed.atTrDizin
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kocaeli_vd_2016.pdf
Size:
121.36 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: